Encoded Therapeutics ETX101 will take center stage at the 29th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT). The event will run from May 11 to May 15, 2026, in Boston, Massachusetts. Encoded Therapeutics confirmed it will present three abstracts during the event. These include one oral presentation and two scientific posters. Moreover, the company will highlight the strength of its vector engineering platform.
The key oral session will appear in the Presidential Symposium. It will feature fresh interim clinical findings from the ongoing POLARIS studies. These studies focus on Encoded Therapeutics ETX101 for patients with SCN1A+ Dravet syndrome. ETX101 is a precision gene-regulation therapy. It is being developed as a one-time treatment option. In addition, the therapy aims to increase SCN1A expression in GABAergic inhibitory neurons. Therefore, it may offer disease-modifying benefits.
Additional Posters Highlight Broader Platform Potential
Encoded Therapeutics will also present two scientific posters. These sessions will showcase broader applications of its research platform. One poster will feature preclinical data on NociPro. This is a novel regulatory element that targets pain-sensing nociceptive neurons. As a result, it may support future chronic pain treatments. The second poster will focus on an intravenously delivered vectorized miRNA approach. This program is designed to unsilence UBE3A. Therefore, it may help advance treatment options for Angelman syndrome.
“We are incredibly proud to present our latest POLARIS data at this prestigious ASGCT platform, showcasing ETX101’s potential to improve seizure control and fundamentally rescue learning and cognitive development in children living with Dravet syndrome,” said Sal Rico, M.D., Ph.D., Chief Medical Officer of Encoded. “Together with our poster presentations, these findings underscore our vector engineering approach and its potential to deliver precision one‑time genetic medicines for neurological disorders.”
Encoded Therapeutics said these presentations further strengthen the promise of Encoded Therapeutics ETX101 and its broader pipeline in neurological disease treatment.
Explore Health Tech Insiders for the latest medical innovations and reliable strategic insights driving the future of technology-driven healthcare transformation.
News Source: Businesswire.com
